Variation in Use of Buprenorphine and Methadone Treatment by Racial, Ethnic, and Income Characteristics of Residential Social Areas in New York City

  • Helena B. HansenEmail author
  • Carole E. Siegel
  • Brady G. Case
  • David N. Bertollo
  • Danae DiRocco
  • Marc Galanter


Opiate agonist therapies for opiate dependence lower HIV incidence and arrest rates among injection drug users,1, 2, 3 thus enhancing access to these treatments is a major public health priority. Buprenorphine, a partial opiate receptor agonist approved by the US FDA in 2002 for treatment of opiate dependence, offers important advantages over methadone maintenance. Buprenorphine is less lethal in overdose than methadone.4 The most commonly prescribed formulation of buprenorphine, in which it is combined with the opiate antagonist naloxone, produces opiate withdrawal when injected, limiting its abuse potential.5 Because of these lower risks, buprenorphine can be prescribed by office-based generalist physicians, potentially increasing treatment access and reducing stigma in comparison to methadone,6 which is restricted to federally regulated methadone clinics.

Few physicians offer buprenorphine treatment despite its advantages.7While policies such as state Medicaid...


York City Buprenorphine Ecological Fallacy Public Clinic Opiate Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was supported by the Substance Abuse and Mental Health Services Administration/American Psychiatric Association Minority Fellowship, the New York State Office of Mental Health’s Center of Excellence in Culturally Competent Mental Health, the Robert Wood Johnson Health and Society Scholars Program, and NIDA grant K01DA032674 (to H. Hansen).

Conflict of Interest

None of the contributing authors have conflicts of interest with regard to ties to manufacturers or promoters of treatments for opiate dependence.


  1. 1.
    Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008;103(9):1493–4.CrossRefGoogle Scholar
  2. 2.
    Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283(10):1303–10PubMedCrossRefGoogle Scholar
  3. 3.
    Appel PW, Joseph H, Kott A, et al. Selected in-treatment outcomes of long-term methadone maintenance treatment patients in New York State. Mt. Sinai Journal of Medicine 2001;68(1):55–61Google Scholar
  4. 4.
    Bell JR, Butler B, Lawrence A, et al. Comparing overdose mortality associated with methadone and buprenorphine. Drug and Alcohol Dependence 2009;104(1–2):73–7PubMedCrossRefGoogle Scholar
  5. 5.
    U.S. Food and Drug Administration: FDA Talk Paper: Subutex and Suboxone approved to treat opiate dependence. Available online at: Accessed March 28, 2013.
  6. 6.
    Merrill JO. Policy progress for physician treatment of opiate addiction. Journal of General Internal Medicine 2002;17(5):361–8PubMedGoogle Scholar
  7. 7.
    Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behavior 2011 36(6):584–9CrossRefGoogle Scholar
  8. 8.
    Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment Prevention and Policy 2008;3:17CrossRefGoogle Scholar
  9. 9.
    Wallack SS, Thomas CP, Martin TC, et al. Substance Abuse Treatment Organizations as Mediators of Social Policy: Slowing the Adoption of a Congressionally Approved Medication. Journal of Behavioral Health Services & Research 2010;37(1):64–78CrossRefGoogle Scholar
  10. 10.
    Roman PM, Abraham AJ, Rothrauff TC, et al. A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2010;38(Suppl 1):S44–S52PubMedCrossRefGoogle Scholar
  11. 11.
    Browne-Miller A. The Praeger International Collection on Addictions. Westport, CT: Greenwood, 2009Google Scholar
  12. 12.
    Benoit E, Young R, Magura S, et al. The impact of welfare reform on methadone treatment: policy lessons from service providers in New York City. Substance Use & Misuse 2004;39(13–14):2355–90CrossRefGoogle Scholar
  13. 13.
    Morgenstern J, Hogue A, Dauber S, et al. A practical clinical trial of coordinated care management to treat substance use disorders among public assistance beneficiaries. J Consult Clin Psychol. 2009;77(2):257–69PubMedCrossRefGoogle Scholar
  14. 14.
    Nunn A, Zeller N, Dickman S, et al. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug and Alcohol Dependence 2011;113(2–3):252CrossRefGoogle Scholar
  15. 15.
    Stanton A, McLeod C, Luckey B, et al. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program. Available online at Accessed March 28, 2013.
  16. 16.
    Massey DS, Denton NA. American Apartheid: Segregation and the Making of the American Underclass. Cambridge, MA: Harvard University Press, 1993Google Scholar
  17. 17.
    Fullilove MT. Rootshock: How Tearing Up City Neighborhoods Hurts America, and What We Can Do About It. New York: Random House, 2005Google Scholar
  18. 18.
    Singer M. Introduction to Syndemics: A Critical Systems Approach to Public and Community Health. San Francisco: John Wiley & Sons, 2009Google Scholar
  19. 19.
    Frank B. An overview of heroin trends in New York City: Past, present and future. The Mount Sinai Journal of Medicine 2000;67(5–6):340–6Google Scholar
  20. 20.
    McNeely N, Gourevitch MN, Paone D, et al. Estimating the prevalence of illicit opioid use in New York City using multiple data sources. BMC Public Health 2012;12:443PubMedCrossRefGoogle Scholar
  21. 21.
    NYC Department of Health and Mental Hygiene. HIV/AIDS Information. Available online at Accessed March 28, 2013.
  22. 22.
    Courtwright DT. The prepared mind: Marie Nyswander, methadone maintenance, and the metabolic theory of addiction. Addiction 1997; 92(3):257–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Grubesic TH, Matisziw TC. On the use of ZIP codes and ZIP code tabulation areas (ZCTAs) for the spatial analysis of epidemiological data. International Journal of Health Geography 2006;5:58CrossRefGoogle Scholar
  24. 24.
    Smith MP, Olatunde O, White C. Inequalities in disability-free life expectancy by area deprivation: England, 2001–04 and 2005–08. Health Statistics Quarterly 2010;48:36–57PubMedCrossRefGoogle Scholar
  25. 25.
    Araujo EM, Costa Mda C, Oliveira NF, et al. Spatial distribution of mortality by homicide and social inequalities according to race/skin color in an intra-urban Brazilian space. Brazilian Review of Epidemiology (Rev Bras Epidemiol) 2010;13(4):549–60CrossRefGoogle Scholar
  26. 26.
    Chau KL. Ecological analysis of health care utilization for China’s rural population: association with a rural county’s socioeconomic characteristics. BMC Public Health 2010;10:664PubMedCrossRefGoogle Scholar
  27. 27.
    Bocquier A, Cortaredona S, Nauleau S, et al. Prevalence of treated diabetes: Geographical variations at the small-area level and their association with area-level characteristics. A multilevel analysis in Southeastern France. Diabetes Metab 2011;37(1):39–46PubMedCrossRefGoogle Scholar
  28. 28.
    Das-Munshi J, Becares L, Dewey ME, et al. Understanding the effect of ethnic density on mental health: multi-level investigation of survey data from England. British Medical Journal 2010;341:c5367PubMedCrossRefGoogle Scholar
  29. 29.
    Gottfredson DC, McNeil RJ, Gottfredson GD. Social area influences on delinquency: A multilevel analysis. Journal of Research in Crime and Delinquency 1991;28(2):197–226CrossRefGoogle Scholar
  30. 30.
    Shevky E, Bell W. Social area analysis: theory, illustrative application and computational procedures. Stanford, CA: Stanford University Press, 1995.Google Scholar
  31. 31.
    Scott-Samuel A. Social area analysis in community medicine. British Journal of Preventive and Social Medicine 1977;31:199–204PubMedGoogle Scholar
  32. 32.
    Heye C, Leuthold H. Theory-based social area analysis: An approach considering the conditions of a post-industrial society. 14 th European Colloquium on Theoretical and Quantitative Geography 2005. Available online at Accessed March 28, 2013.
  33. 33.
    Adams PR, Martinez ME, Vickerie JL. Summary health statistics for the U.S. population: national health interview survey, 2009. Vital Health Statistics 2009;10(248):1–115Google Scholar
  34. 34.
    Liao Y, Bang D, Cosgrove S, et al. Surveillance of health status in minority communities—racial and ethnic approaches to community health across the U.S. (REACH U.S.) risk factor survey, United States 2009. MMWR Surveillance Summary 2011;60(60):1–44.Google Scholar
  35. 35.
    SAS Institute, Inc. SAS/STAT® 9.2 User’s Guide. Cary, NC: SAS Institute Inc.; 2008Google Scholar
  36. 36.
    Taylor C. New option to wean off heroin. New York City Newsday. Available online at . Accessed March 28, 2013.
  37. 37.
    Duhan D, Johnson S, Wilcox J, et al. Influences on consumer use of word-of-mouth recommendation sources. Journal of the Academy of Marketing Science 2007;25(4):283–95CrossRefGoogle Scholar
  38. 38.
    Casadonte P. Community treatment programs take up buprenorphine. Science & Practice Perspectives 2004; 2(2):24–6.CrossRefGoogle Scholar
  39. 39.
    Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients, Journal of General Internal Medicine 2007;22(4):527–30.PubMedCrossRefGoogle Scholar
  40. 40.
    National Alliance of Advocates for Buprenorphine Treatment. National Alliance of Advocates for Buprenorphine Treatment (NAABT). Available online at Accessed March 28, 2013.
  41. 41.
    Van Zee, A. The promotion and marketing of OxyContin: Commercial triumph, public health tragedy. Journal of the American Public Health Association 2009;99(2):221–7CrossRefGoogle Scholar
  42. 42.
    Substance Abuse and Mental Health Services Administration (SAMHSA). Buprenorphine Physician and Treatment Program Locator. Available online at Accessed March 28, 2013.
  43. 43.
    Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. Journal of General Internal Medicine 2010;25(9):936–41.PubMedCrossRefGoogle Scholar
  44. 44.
    Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. Journal of General Internal Medicine 2009;24(2):218–25PubMedCrossRefGoogle Scholar
  45. 45.
    Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug and Alcohol Dependence 2009;99(1–3): 222–30PubMedCrossRefGoogle Scholar
  46. 46.
    Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. Journal of Substance Abuse Treatment 2010;39(4):340–52PubMedCrossRefGoogle Scholar
  47. 47.
    Sullivan LE, Moore BA, O’Connor PG, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. American Journal of Addictions 2010;19(1):53–8CrossRefGoogle Scholar
  48. 48.
    Link B. Epidemiological sociology and the social shaping of population health. Journal of Health and Social Behavior 2008;49:367–84PubMedCrossRefGoogle Scholar
  49. 49.
    Rubin MS, Colen CG, Link G. Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. American Journal of Public Health 2009;100(6):1053–9CrossRefGoogle Scholar
  50. 50.
    Cutchin MP. The need for the “New Health Geography” in epidemiological studies of environment and health. Health Place 2007;13(3):725–42PubMedCrossRefGoogle Scholar
  51. 51.
    Honberg R, Kimball A, Diehl S, et al. State mental health cuts: the continuing crisis. National Alliance for the Mentally Ill (NAMI). Available online at Accessed March 28, 2013.
  52. 52.
    New York Association of Alcoholism & Substance Abuse Providers (NYAASAP). Federal funding for addiction-related programming critical, especially in the face of budget cuts. Available online at Accessed March 28, 2013.

Copyright information

© National Council for Community Behavioral Healthcare 2013

Authors and Affiliations

  • Helena B. Hansen
    • 1
    • 2
    • 3
    Email author
  • Carole E. Siegel
    • 3
  • Brady G. Case
    • 4
  • David N. Bertollo
    • 3
  • Danae DiRocco
    • 5
  • Marc Galanter
    • 1
  1. 1.Division of Alcoholism and Drug AbuseNew York University Medical CenterNew YorkUSA
  2. 2.Department of AnthropologyNew York UniversityNew YorkUSA
  3. 3.Statistics and Services Research DivisionNathan Kline Institute for Psychiatric ResearchOrangeburgUSA
  4. 4.Bradley-Hasbro Children’s Research CenterBradley Hospital and Hasbro Children’s HospitalProvidenceUSA
  5. 5.The Commonwealth Medical CollegeScrantonUSA

Personalised recommendations